GlassScriptPhysician profile
Rizwan K Alimohammad
NPI 1750546008
$349,275.94
in general payments reported to CMS, 2019-2025
37 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $24K · 2021: $30K · 2022: $24K · 2023: $102K · 2024: $87K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Consulting Fee: $102K · Food and Beverage: $17K · Travel and Lodging: $8,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,225.00 |
| Consulting Fee | $101,706.25 |
| Food and Beverage | $16,713.26 |
| Travel and Lodging | $8,616.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $109,562.96 | 2019-2025 | Emblem Mri S-Icd, General - Brady, Farapulse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105,188.25 | 2019-2025 | Lifevest |
| Cvrx, INC. | $52,226.88 | 2021-2025 | Barostim Neo System |
| Medical Device Business Services, INC. | $44,300.00 | 2021-2025 | Carto 3 |
| Atricure, INC. | $11,644.83 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Medtronic Vascular, INC. | $10,379.88 | 2019-2020 | |
| Biosense Webster, INC. | $8,299.95 | 2020-2025 | Carto 3, Octaray Mapping Catheter |
| Edwards Lifesciences Corporation | $2,651.79 | 2020-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $1,375.18 | 2019-2025 | |
| Medtronic, INC. | $561.12 | 2021-2025 | Mycarelink |
| Pfizer INC. | $476.00 | 2019-2025 | |
| Abbott Laboratories | $414.65 | 2020-2025 | Mitraclip, Navitor, Perclose Prostyle |
| Janssen Pharmaceuticals, INC | $369.58 | 2019-2022 | |
| Amgen INC. | $338.91 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $219.12 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $195.65 | 2025 | Rapiblyk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.73 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $168.92 | 2019-2023 | Camzyos |
| Abiomed | $119.60 | 2019-2024 | Impella |
| Biotronik INC. | $98.41 | 2023 | Biomonitor, Acticor 7 Vr-T Dx |
| Gilead Sciences, INC. | $62.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.06 | 2019 | |
| Itamar Medical INC | $48.18 | 2023 | Watchpatone |
| Sanofi-Aventis U.S. LLC | $37.62 | 2019-2023 | |
| Scpharmaceuticals INC. | $37.41 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $36.54 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $33.89 | 2023 | Verquvo |
| Genzyme Corporation | $33.26 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $32.25 | 2023-2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $23.84 | 2019 | |
| Glaxosmithkline, LLC. | $21.35 | 2025 | Arexvy |
| Kestra Medical Technology Services, INC. | $20.21 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $17.90 | 2025 | Attruby |
| Novo Nordisk INC | $15.88 | 2023 | |
| Baxter Healthcare | $15.13 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $13.31 | 2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $10.73 | 2023 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Alimohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.